Literature DB >> 30895483

Living Donor Liver Transplantation for Hepatocellular Carcinoma: An Asian Perspective.

Young-In Yoon1, Sung-Gyu Lee2.   

Abstract

Despite advancements in early diagnosis and medico-surgical treatment, hepatocellular carcinoma (HCC) is still a major cancer that causes substantial mortality in Asian countries. Liver transplantation (LT) has been accepted worldwide as the most effective treatment modality for patients with HCC; however, with the high incidence of HCC and low organ donation rate, Asia has developed distinctive features of indications and strategies for the application of LT. Unlike Western countries, living donor liver transplantation (LDLT) accounts for most LT cases for HCC in Asian countries, and most major transplantation centers perform LDLT for HCC patients with extended criteria. This article reviewed the current practice and outcome of LDLT for HCC from an Asian perspective and summarized the strategies that the high-volume LT centers in Asia use to obtain satisfactory oncologic results.

Entities:  

Keywords:  Asia; Hepatocellular carcinoma; Liver transplantation; Living donors

Mesh:

Year:  2019        PMID: 30895483     DOI: 10.1007/s10620-019-05551-4

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  57 in total

1.  The possibility of radiotherapy as downstaging to living donor liver transplantation for hepatocellular carcinoma with portal vein tumor thrombus.

Authors:  Jin Y Choi; Jeong I Yu; Hee C Park; C H David Kwon; Jong M Kim; Jae-Won Joh; Gyu-Seong Choi; Jae B Park; Sung J Kim; Seung H Lee; Won-Tae Cho; Kyo W Lee; Byeong-Gon Na; Dong Kyu Oh; Nuri Lee; Chan W Cho; Sanghoon Lee; Suk-Koo Lee
Journal:  Liver Transpl       Date:  2017-04       Impact factor: 5.799

2.  ABO-Incompatible Living Donor Liver Transplantation in Focus of Antibody Rebound.

Authors:  Silke Rummler; Astrid Bauschke; Erik Baerthel; Heike Juette; Katrin Maier; Christina Malessa; Dagmar Barz; Utz Settmacher
Journal:  Transfus Med Hemother       Date:  2016-11-09       Impact factor: 3.747

3.  The relationship between recurrences and immunosuppression on living donor liver transplantation for hepatocellular carcinoma.

Authors:  S Miyagi; N Kawagishi; S Sekiguchi; Y Akamatsu; K Sato; I Takeda; Y Kobayashi; K Tokodai; K Fujimori; S Satomi
Journal:  Transplant Proc       Date:  2012-04       Impact factor: 1.066

4.  Prevention of hepatocellular carcinoma in the Asia-Pacific region: consensus statements.

Authors: 
Journal:  J Gastroenterol Hepatol       Date:  2010-04       Impact factor: 4.029

Review 5.  Living donor liver transplantation for hepatocellular cancer: an (almost) exclusive Eastern procedure?

Authors:  Rafael S Pinheiro; Daniel R Waisberg; Lucas S Nacif; Vinicius Rocha-Santos; Rubens M Arantes; Liliana Ducatti; Rodrigo B Martino; Quirino Lai; Wellington Andraus; Luiz A C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2017-08-29

6.  Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center.

Authors:  Sung-Gyu Lee; Shin Hwang; Deok-Bog Moon; Chul-Soo Ahn; Ki-Hun Kim; Kyu-Bo Sung; Gi-Young Ko; Kwang-Min Park; Tae-Yong Ha; Gi-Won Song
Journal:  Liver Transpl       Date:  2008-07       Impact factor: 5.799

Review 7.  Role of liver transplantation for hepatocellular carcinoma.

Authors:  Vinay Kumaran
Journal:  J Clin Exp Hepatol       Date:  2014-01-23

Review 8.  Liver transplantation for hepatocellular carcinoma in Asia.

Authors:  Vanessa de Villa; Chung Mau Lo
Journal:  Oncologist       Date:  2007-11

9.  Efficacy of sorafenib after liver transplantation in patients with primary hepatic carcinoma exceeding the Milan criteria: a preliminary study.

Authors:  Lei Huang; Guang-Ming Li; Ji-Ye Zhu; Zhao Li; Tao Li; Xi-Sheng Leng
Journal:  Onco Targets Ther       Date:  2012-12-20       Impact factor: 4.147

Review 10.  Liver transplantation for hepatocellular carcinoma: outcomes and treatment options for recurrence.

Authors:  Robert S Rahimi; James F Trotter
Journal:  Ann Gastroenterol       Date:  2015 Jul-Sep
View more
  7 in total

1.  Recipient hepatectomy under total hepatic vascular exclusion to prevent hepatocellular carcinoma spread in living donor liver transplantation.

Authors:  Young-In Yoon; Shin Hwang; Deok-Bog Moon; Dong-Hwan Jung; Sung-Gyu Lee
Journal:  Korean J Transplant       Date:  2021-06-07

2.  Inflammation-Based Prognostic Scores in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma After Liver Transplantation.

Authors:  Ao Ren; Zhongqiu Li; Xuzhi Zhang; Ronghai Deng; Yi Ma
Journal:  J Hepatocell Carcinoma       Date:  2020-07-07

Review 3.  Current perspectives on the immunosuppressive tumor microenvironment in hepatocellular carcinoma: challenges and opportunities.

Authors:  Chen Lu; Dawei Rong; Betty Zhang; Wubin Zheng; Xuehao Wang; Ziyi Chen; Weiwei Tang
Journal:  Mol Cancer       Date:  2019-08-29       Impact factor: 27.401

4.  Liver transplantation with simultaneous splenectomy increases risk of cancer development and mortality in hepatocellular carcinoma patients.

Authors:  Hsiu-Lung Fan; Chung-Bao Hsieh; Shih-Ming Kuo; Teng-Wei Chen
Journal:  World J Gastrointest Surg       Date:  2022-09-27

5.  Integrating machine learning to construct aberrant alternative splicing event related classifiers to predict prognosis and immunotherapy response in patients with hepatocellular carcinoma.

Authors:  Wangrui Liu; Shuai Zhao; Wenhao Xu; Jianfeng Xiang; Chuanyu Li; Jun Li; Han Ding; Hailiang Zhang; Yichi Zhang; Haineng Huang; Jian Wang; Tao Wang; Bo Zhai; Lei Pan
Journal:  Front Pharmacol       Date:  2022-10-03       Impact factor: 5.988

6.  Are the criteria always right? Assessment of hepatocellular carcinoma cases in living zzm321990donor liver transplantation at a high-volume center

Authors:  Yücel Yankol; Gültekin Hoş; Turan Kanmaz; Nesimi Mecit; Yilmaz Çakaloğlu; Münci Kalayoğlu; Koray S Acarli
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

7.  The immunomodulatory activity of lenvatinib prompts the survival of patients with advanced hepatocellular carcinoma.

Authors:  Jie Zhu; Peiqi Fang; Chong Wang; Meixiu Gu; Baishen Pan; Wei Guo; Xinrong Yang; Beili Wang
Journal:  Cancer Med       Date:  2021-10-04       Impact factor: 4.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.